Table 2.
The effects of the surface functionalization and N/P ratio of GO-based carriers on gene silencing in breast cancer cells.
| GO Modification | Payload Type (Targeting Agent) |
N/P Ratio (w/w) |
Gene Silencing | Cell Type |
|---|---|---|---|---|
| PEG | a miRNA 101 (PLA) [62] | 1−3.8 | - | MCF-7, MDA-MB-231 |
| a cd-siRNA (R8) [70] | 10 | - | ||
| a P-gp siRNA (FA) [88] | 4 | 70% | ||
| b Rictor siRNA (R8) [67] | 0.5 | 70% | ||
| a EPAC1-siRNA [17] | 2 | 62% | MDA-MB-231 | |
| PAMAM | a EPAC1-siRNA [17] | 2 | 62% | MDA-MB-231 |
| b miR-21i [16] | - | - | ||
| b MMP-9 shRNA [87] | 10 | 52% | MCF-7 | |
| PEI | a P-gp siRNA (FA) [88] | 4 | 70% | MCF-7, MDA-MB-231 |
| b Rictor siRNA (R8) [67] | 0.5 | 70% | ||
| Chitosan |
b Survivin siRNA (anti-EpCAM) [51] |
30 | 44% | MCF-7 |
| a HIF-1α siRNA (HA) [65] | 6.5 | 62% | 4T1 | |
| a EGFR siRNA (FA) [66] | - | - | MCF-7, MDA-MB-231 |
|
| Peptide | a cd-siRNA (R8) [70] | 10 | - | MCF-7, MDA-MB-231 |
| b Rictor siRNA (R8) [67] | 0.5 | 70% | ||
|
b Survivin siRNA (anti-HER2) [64] |
40 | 50% | MCF-7 |
a in vitro; b in vitro and in vivo.